NASDAQ:SIBN SiBone (SIBN) Stock Price, News & Analysis $14.68 -0.13 (-0.88%) Closing price 04:00 PM EasternExtended Trading$15.28 +0.60 (+4.05%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About SiBone Stock (NASDAQ:SIBN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SiBone alerts:Sign Up Key Stats Today's Range$14.46▼$15.1050-Day Range$11.61▼$14.8452-Week Range$11.48▼$21.89Volume306,450 shsAverage Volume885,427 shsMarket Capitalization$651.06 millionP/E RatioN/ADividend YieldN/APrice Target$23.00Consensus RatingModerate Buy Company Overview Si-BONE, Inc. is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain. FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation. These advances aim to streamline instrumentation, reduce surgical time and enhance early postoperative stability. Si-BONE’s development pipeline focuses on novel implant geometries and ancillary fixation solutions to broaden clinical indications and address adjacent biomechanical targets. Headquartered in Santa Clara, California, Si-BONE markets its products through a dedicated direct sales organization in the United States and a network of distributors and strategic partners across Europe, Asia-Pacific and Latin America. The company supports a growing base of orthopedic and neurosurgeons through surgeon education programs, hands-on cadaver labs and a robust clinical registry that tracks real-world outcomes. Founded in 2008, Si-BONE has built a compelling evidence package supported by peer-reviewed publications, prospective trials and retrospective analyses. Management continues to leverage its clinical research platform to validate the long-term safety and efficacy of its implants while exploring opportunities to expand its technology into complementary spinal indications.AI Generated. May Contain Errors. Read More SiBone Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreSIBN MarketRank™: SiBone scored higher than 48% of companies evaluated by MarketBeat, and ranked 541st out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingSiBone has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialSiBone has a consensus price target of $23.00, representing about 56.7% upside from its current price of $14.68.Amount of Analyst CoverageSiBone has only been the subject of 2 research reports in the past 90 days.Read more about SiBone's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for SiBone are expected to grow in the coming year, from ($0.44) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SiBone is -37.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SiBone is -37.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSiBone has a P/B Ratio of 3.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about SiBone's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.67% of the float of SiBone has been sold short.Short Interest Ratio / Days to CoverSiBone has a short interest ratio ("days to cover") of 9.12.Change versus previous monthShort interest in SiBone has recently decreased by 2.05%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSiBone does not currently pay a dividend.Dividend GrowthSiBone does not have a long track record of dividend growth. News and Social Media1.1 / 5News Sentiment-0.22 News SentimentSiBone has a news sentiment score of -0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for SiBone this week, compared to 2 articles on an average week. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, SiBone insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $418,831.00 in company stock.Percentage Held by Insiders4.00% of the stock of SiBone is held by insiders.Percentage Held by Institutions98.11% of the stock of SiBone is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about SiBone's insider trading history. Receive SIBN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SiBone and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SIBN Stock News HeadlinesSiBone (NASDAQ:SIBN) SVP Sells 3,726 SharesMay 21 at 8:07 AM | insidertrades.comAnshul Maheshwari, CFO of SI-BONE, sells $60k in SIBN stockMay 15, 2026 | investing.comI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, Amazon, Snap, and Block have done the same. Most assume this is about AI - but investor Porter Stansberry says the real driver runs far deeper. Goldman Sachs estimates 12,400 Americans are being financially harmed every day by this shift, while others grow wealthier. Stansberry - who predicted the internet economy's rise and recommended Amazon, Qualcomm, and Texas Instruments before they were household names - is now releasing a new investigation he calls The Final Displacement.May 22 at 1:00 AM | Porter & Company (Ad)SI-BONE targets $230M-$233M 2026 revenue while CMS proposes new DRGs that could add up to $50,000 per Granite procedureMay 14, 2026 | seekingalpha.comSiBone (NASDAQ:SIBN) Given Buy Rating at Truist FinancialMay 13, 2026 | americanbankingnews.comSI-BONE, Inc. (SIBN) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comSI-BONE, Inc. (SIBN) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comSI-BONE, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 12, 2026 | seekingalpha.comSee More Headlines SIBN Stock Analysis - Frequently Asked Questions How have SIBN shares performed this year? SiBone's stock was trading at $19.72 at the start of the year. Since then, SIBN shares have decreased by 25.6% and is now trading at $14.68. How were SiBone's earnings last quarter? SiBone (NASDAQ:SIBN) issued its quarterly earnings results on Monday, May, 11th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.07. The company earned $52.59 million during the quarter, compared to the consensus estimate of $51.16 million. SiBone had a negative net margin of 8.10% and a negative trailing twelve-month return on equity of 9.56%. Read the conference call transcript. Does SiBone have any subsidiaries? SiBone subsidiaries include these companies: SI-BONE Deutschland GmbH, SI-BONE S.R.L., and SI-BONE UK LTD. When did SiBone IPO? SiBone (SIBN) raised $84 million in an IPO on Wednesday, October 17th 2018. The company issued 6,000,000 shares at a price of $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers. Who are SiBone's major shareholders? SiBone's top institutional investors include First Light Asset Management LLC (12.07%), Granahan Investment Management LLC (3.92%), Paradigm Capital Management Inc. NY (2.54%) and Dimensional Fund Advisors LP (1.40%). Insiders that own company stock include Laura Francis, Michael A Pisetsky, Anshul Maheshwari, Anthony J Recupero, John Gordon Freund, Mika Nishimura and Timothy E Davis Jr. View institutional ownership trends. How do I buy shares of SiBone? Shares of SIBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SiBone own? Based on aggregate information from My MarketBeat watchlists, some other companies that SiBone investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Humana (HUM), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings5/11/2026Today5/22/2026Next Earnings (Estimated)8/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 SIBN's financial health is in the Red zone, according to TradeSmith. SIBN has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:SIBN CIK1459839 Webwww.si-bone.com Phone(408) 207-0700FaxN/AEmployees350Year Founded2008Price Target and Rating Average Price Target for SiBone$23.00 High Price Target$27.00 Low Price Target$18.00 Potential Upside/Downside+56.7%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.90 million Net Margins-8.10% Pretax Margin-8.10% Return on Equity-9.56% Return on Assets-7.06% Debt Debt-to-Equity Ratio0.20 Current Ratio9.99 Quick Ratio8.34 Sales & Book Value Annual Sales$200.93 million Price / Sales3.24 Cash FlowN/A Price / Cash FlowN/A Book Value$4.03 per share Price / Book3.64Miscellaneous Outstanding Shares44,350,000Free Float42,575,000Market Cap$651.06 million OptionableOptionable Beta0.67 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:SIBN) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredOne algorithm, 17 years, nearly 2,000% total returnsA physicist in Dublin claims his AI algorithm has beaten the market for 17 consecutive years - with nearly 2,0...Porter & Company | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredRevealed: The Best Kept Secrets On Wall StreetTom Busby, founder of the Diversified Trading Institute, is giving away his 'Little Black Book' - a collection...DTI Trader | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SiBone Please log in to your account or sign up in order to add this asset to your watchlist. Share SiBone With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
